Etropal AD (XBUL:ETR) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XBUL:ETR Etropal AD XBUL:ETR
50 GF Score
Price €2.66
GF Value €8.81
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Etropal AD 5-Year Yield-on-Cost %?

Etropal AD XBUL:ETR 50 5-Year Yield-on-Cost % is 0.00 as of Aug. 31, 2026. GuruFocus rates XBUL:ETR with a GF Score™ of 50/100 and a GF Value™ of €8.81 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 316 Medical Devices & Instruments companies, Etropal AD ranks worse than 316455.38% on this metric.

Etropal AD's yield on cost for the quarter that ended in Dec. 2025 was 0.00.


The historical rank and industry rank for Etropal AD's 5-Year Yield-on-Cost % or its related term are showing as below:



XBUL:ETR's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.405
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Etropal AD  (XBUL:ETR) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Etropal AD 5-Year Yield-on-Cost % Related Terms


XBUL:ETR vs ISRG, BDX, RMD: 5-Year Yield-on-Cost % Comparison

For the Medical Instruments & Supplies subindustry, Etropal AD's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Etropal AD 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Etropal AD's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Etropal AD's 5-Year Yield-on-Cost % falls into.


XBUL:ETR
50GF Score
Etropal AD XBUL:ETR
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Etropal AD 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Etropal AD is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Etropal AD (XBUL:ETR) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 31, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Etropal AD and its competitors. According to the industry distribution chart, Etropal AD ranks #999999 out of 316 companies in the Medical Devices & Instruments industry.
Is Etropal AD's 5-Year Yield-on-Cost % too high?
Etropal AD's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Etropal AD ranks #999999 out of 316 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Etropal AD has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Etropal AD's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Etropal AD ranks #999999 out of 316 companies for 5-Year Yield-on-Cost %. This places Etropal AD in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.41, based on 316 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Etropal AD and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Etropal AD's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Etropal AD stock overvalued right now?
Based on GuruFocus' analysis, Etropal AD (XBUL:ETR) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.81, compared to a current price of €2.66 — trading 69.8% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Etropal AD's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Etropal AD (XBUL:ETR), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Etropal AD (XBUL:ETR) Overvalued in 2026?

Based on GuruFocus' analysis, Etropal AD stock appears to be undervalued. The current stock price of €2.66 is trading 69.8% below its estimated GF Value™ of €8.81. GuruFocus considers Etropal AD to be Significantly Undervalued.

Key valuation signals for XBUL:ETR:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: €8.81 vs. price of €2.66 (69.8% below fair value)
  • GF Score™: 50/100 with 3 warning signs

No single metric tells the full story. See the XBUL:ETR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Etropal AD Business Description

Address 191 Rusky Boulevard, Etropole, Sofia, BGR, 2180
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
50GF Score

Get the complete analysis for XBUL:ETR

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.66
Price
€8.81
GF Value